(Sept. 29, 2014) In a perspective piece for the website MedPage Today, representatives from the Society of Gynecologic Oncology discuss clinical endpoints appropriate for studies addressing the “unique characteristics” of ovarian cancer and progress toward improving outcomes for women affected by the disease.
In the article, co-authors Thomas J. Herzog, MD, of the University of Cincinnati Cancer Institute, and SGO President-Elect Robert L. Coleman, MD, of the University of Texas MD Anderson Cancer Center in Houston call for the adoption of more varied clinical endpoint in trials for ovarian cancer. In particular, they worry that the reliance on overall survival doesn’t mesh with the multiple-treatment strategy many patients with ovarian cancer receive.
Click here to read the article.
